Get brand name WELLBUTRIN XL® (bupropion HCI) extended release tablets at a co-pay price similar to or lower than the generic versions. Eligible patients* pay as little as $4 for each 30-day supply for up to 12 uses (up to a $50 savings for each 30-day supply).

Please click here or scroll down for Important Safety Information, including a Warning regarding antidepressants and suicidality.

Answer the questions below and download your Savings Card.

Do you purchase your prescription medication through Medicare, Medicaid, or other federal or state prescription drug program?

Do you live in Massachusetts and/or have insurance coverage for prescriptions in Massachusetts?





For Privacy Statement, please click here.

*Please note: Offer is not valid for prescriptions being fully or partially reimbursed under Medicaid, a Medicare drug benefit plan, or other federal or state programs (such as medical assistance programs). This card is not valid for Massachusetts residents or where otherwise prohibited by law. The patient is responsible for reporting receipt of this offer to any health insurer, health plan, or third-party payer as may be required. By using this card, you agree that you will not submit a claim for the prescription to a government payer. If any part of your prescription is paid for by a nongovernmental third-party payer, you attest to having disclosed this offer to your third-party payer. The use of this card is subject to applicable state and federal law.

The Savings Card is redeemable only when accompanied by a valid prescription.

INDICATION

WELLBUTRIN XL® is indicated for the treatment of major depressive disorder.

IMPORTANT SAFETY INFORMATION

WARNING

Suicidality and Antidepressant Drugs

Use in Treating Psychiatric Disorders: Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other disorders. Anyone considering the use of WELLBUTRIN XL or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. WELLBUTRIN XL is not approved for use in pediatric patients.

Use in Smoking Cessation Treatment: WELLBUTRIN®, WELLBUTRIN SR®, and WELLBUTRIN XL are not approved for smoking cessation treatment, but bupropion under the name ZYBAN® is approved for this use. Serious neuropsychiatric events, including but not limited to depression, suicidal ideation, suicide attempt, and completed suicide have been reported in patients taking bupropion for smoking cessation. Some cases may have been complicated by the symptoms of nicotine withdrawal in patients who stopped smoking. Depressed mood may be a symptom of nicotine withdrawal. Depression, rarely including suicidal ideation, has been reported in smokers undergoing a smoking cessation attempt without medication. However, some of these symptoms have occurred in patients taking bupropion who continued to smoke.

All patients being treated with bupropion for smoking cessation treatment should be observed for neuropsychiatric symptoms including changes in behavior, hostility, agitation, depressed mood, and suicide-related events, including ideation, behavior, and attempted suicide. These symptoms, as well as worsening of pre-existing psychiatric illness and completed suicide, have been reported in some patients attempting to quit smoking while taking ZYBAN in the post-marketing experience. When symptoms were reported, most were during treatment with ZYBAN, but some were following discontinuation of treatment with ZYBAN. These events have occurred in patients with and without pre-existing psychiatric disease; some have experienced worsening of their psychiatric illnesses. Patients with serious psychiatric illness such as schizophrenia, bipolar disorder, and major depressive disorder did not participate in the premarketing studies of ZYBAN.

Advise patients and caregivers that the patient using bupropion for smoking cessation should stop taking bupropion and contact a healthcare provider immediately if agitation, hostility, depressed mood, or changes in thinking or behavior that are not typical for the patient are observed, or if the patient develops suicidal ideation or suicidal behavior In many post-marketing cases, resolution of symptoms after discontinuation of ZYBAN was reported, although in some cases the symptoms persisted; therefore, ongoing monitoring and supportive care should be provided until symptoms resolve.

The risks of using bupropion for smoking cessation should be weighed against the benefits of its use. ZYBAN has been demonstrated to increase the likelihood of abstinence from smoking for as long as six months compared to treatment with placebo. The health benefits of quitting smoking are immediate and substantial.

WELLBUTRIN XL® is not for everyone. There is a chance of having a seizure (convulsion, fit) with WELLBUTRIN XL®, especially in people with certain medical problems or who take certain medicines. The risk of having seizures increases with higher doses of WELLBUTRIN XL®. Tell your doctor about all of your medical conditions, especially if you have liver or kidney problems, and all the medicines you take. Do not take any other medicines while you are using WELLBUTRIN XL® unless your doctor has said it is okay to take them. If you have a seizure while taking WELLBUTRIN XL®, stop taking the tablets and call your doctor right away. Do not take WELLBUTRIN XL® again if you have a seizure.

Do not take with monoamine oxidase inhibitors (MAOIs), or medicines that contain bupropion like ZYBAN®, which is used to help patients stop smoking. Some people get high blood pressure that can be severe while taking WELLBUTRIN XL®. The risk for high blood pressure may be increased if you also use nicotine replacement therapy (such as a nicotine patch) to help you stop smoking.

Who should not take WELLBUTRIN XL®:

Do not take WELLBUTRIN XL® if you:

  • Have or had a seizure disorder or epilepsy
  • Are taking ZYBAN® (used to help people stop smoking) or any other medicines that contain bupropion hydrochloride, such as WELLBUTRIN® Tablets or WELLBUTRIN SR® Sustained-Release Tablets. Bupropion is the same active ingredient that is in WELLBUTRIN XL®
  • Drink a lot of alcohol and abruptly stop drinking, or use medicines called sedatives (these make you sleepy) or benzodiazepines and you stop using them all of a sudden
  • Have taken within the last 14 days medicine for depression called a monoamine oxidase inhibitor (MAOI), such as NARDIL® (phenelzine sulfate), PARNATE® (tranylcypromine sulfate), or MARPLAN® (isocarboxazid)
  • Have or had an eating disorder such as anorexia nervosa or bulimia
  • Are allergic to the active ingredient in WELLBUTRIN XL®, bupropion, or to any of the inactive ingredients

Possible side effects of WELLBUTRIN XL®:

The most common adverse reactions reported with WELLBUTRIN XL® are weight loss, dry mouth, nausea, difficulty sleeping, dizziness, and sore throat. Other common side effects include loss of appetite, skin rash, sweating, ringing in the ears, shakiness, stomach pain, agitation, anxiety, muscle pain, fast heartbeat, and more frequent urination.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.


Trademarks are the property of their respective owners.


Please see full Product Information, including Medication Guide, click here.

This information is not intended to replace professional medical advice. Only a doctor can diagnose depression.



Terms and Conditions

This card is redeemable only when accompanied by a valid prescription. Pay as little as $4 for each 30-day supply for up to 12 uses (up to $50 savings for each 30-day supply).

  • Pharmacist instructions for a patient with an Eligible Third-Party Payer
  • -   Submit the claim to the primary Third-Party Payer first, then submit the balance due to Therapy First Plus as a Secondary Payer as a co-pay only billing using a valid Other Coverage Code, (eg, 8). The patient is responsible for the first $4 and the card pays up to the next $50. Reimbursement will be received from Therapy First Plus.

  • Pharmacist instructions for a cash-paying patient
  • -   Submit this claim to Therapy First Plus. A valid Other Coverage Code (eg, 1) is required. The patient is responsible for the first $4 and the card pays up to the next $50. Reimbursement will be received from Therapy First Plus.

    -   Valid Other Coverage Code required. For any questions regarding Therapy First Plus online processing, please call the Help Desk at 1-800-422-5604.

    -   Card not valid for prescriptions reimbursed under Medicaid, a Medicare drug benefit plan, or any other federal or state programs (such as medical assistance programs). This card is not valid for Massachusetts residents or where otherwise prohibited by law. The patient is responsible for reporting receipt of this offer to any health insurer, health plan, or third-party payer as may be required. Offer not valid for patients younger than 18 years. Patients with questions should call 1-855-859-2966.

Program expires 12/31/14. Programs managed by PSKW & Associates on behalf of Valeant Pharmaceuticals North America LLC. The parties reserve the right to amend or end these programs at any time. Product dispensed pursuant to program rules and federal and state laws.

WELLBUTRIN XL is a registered trademark of GlaxoSmithKline.


©2013 Valeant Pharmaceuticals North America LLC                                          12/13 Printed in USA                                                                                                    WXL108-0512a